MLSS Quote, Financials, Valuation and Earnings

Embecta has a net margin of -58.13% compared to Milestone Scientific's net margin of --. Milestone Scientific's return on equity of -61.33% beat Embecta's return on equity of --.

Milestone Scientific has a consensus price target of --, signalling upside risk potential of 131%. On the other hand Embecta has an analysts' consensus of $22.00 which suggests that it could grow by 69.23%. Given that Milestone Scientific has higher upside potential than Embecta, analysts believe Milestone Scientific is more attractive than Embecta.

Milestone Scientific has a beta of 1.409, which suggesting that the stock is 40.929% more volatile than S&P 500. In comparison Embecta has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Milestone Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Embecta offers a yield of 4.62% to investors and pays a quarterly dividend of $0.15 per share. Milestone Scientific pays -- of its earnings as a dividend. Embecta pays out 44.06% of its earnings as a dividend. Embecta's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Milestone Scientific quarterly revenues are $2.5M, which are smaller than Embecta quarterly revenues of $261.9M. Milestone Scientific's net income of -$1.5M is lower than Embecta's net income of --. Notably, Milestone Scientific's price-to-earnings ratio is -- while Embecta's PE ratio is 13.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Milestone Scientific is 8.13x versus 0.68x for Embecta. Usually stocks with elevated PS ratios are considered overvalued.

Gossamer Bio has a net margin of -58.13% compared to Milestone Scientific's net margin of -324.93%. Milestone Scientific's return on equity of -61.33% beat Gossamer Bio's return on equity of --.

Milestone Scientific has a consensus price target of --, signalling upside risk potential of 131%. On the other hand Gossamer Bio has an analysts' consensus of $7.61 which suggests that it could grow by 485.17%. Given that Gossamer Bio has higher upside potential than Milestone Scientific, analysts believe Gossamer Bio is more attractive than Milestone Scientific.

Milestone Scientific has a beta of 1.409, which suggesting that the stock is 40.929% more volatile than S&P 500. In comparison Gossamer Bio has a beta of 1.861, suggesting its more volatile than the S&P 500 by 86.09%.

Milestone Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gossamer Bio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Milestone Scientific pays -- of its earnings as a dividend. Gossamer Bio pays out -- of its earnings as a dividend.

Milestone Scientific quarterly revenues are $2.5M, which are smaller than Gossamer Bio quarterly revenues of $9.5M. Milestone Scientific's net income of -$1.5M is higher than Gossamer Bio's net income of -$30.8M. Notably, Milestone Scientific's price-to-earnings ratio is -- while Gossamer Bio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Milestone Scientific is 8.13x versus -- for Gossamer Bio. Usually stocks with elevated PS ratios are considered overvalued.

Inogen has a net margin of -58.13% compared to Milestone Scientific's net margin of -12.18%. Milestone Scientific's return on equity of -61.33% beat Inogen's return on equity of -19.02%.

Milestone Scientific has a consensus price target of --, signalling upside risk potential of 131%. On the other hand Inogen has an analysts' consensus of $10.00 which suggests that it could grow by 34.23%. Given that Milestone Scientific has higher upside potential than Inogen, analysts believe Milestone Scientific is more attractive than Inogen.

Milestone Scientific has a beta of 1.409, which suggesting that the stock is 40.929% more volatile than S&P 500. In comparison Inogen has a beta of 1.155, suggesting its more volatile than the S&P 500 by 15.471%.

Milestone Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Milestone Scientific pays -- of its earnings as a dividend. Inogen pays out -- of its earnings as a dividend.

Milestone Scientific quarterly revenues are $2.5M, which are smaller than Inogen quarterly revenues of $80.1M. Milestone Scientific's net income of -$1.5M is higher than Inogen's net income of -$9.8M. Notably, Milestone Scientific's price-to-earnings ratio is -- while Inogen's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Milestone Scientific is 8.13x versus 0.52x for Inogen. Usually stocks with elevated PS ratios are considered overvalued.

Lucid Diagnostics has a net margin of -58.13% compared to Milestone Scientific's net margin of -1055.55%. Milestone Scientific's return on equity of -61.33% beat Lucid Diagnostics's return on equity of -650.37%.

Milestone Scientific has a consensus price target of --, signalling upside risk potential of 131%. On the other hand Lucid Diagnostics has an analysts' consensus of $3.50 which suggests that it could grow by 173.44%. Given that Lucid Diagnostics has higher upside potential than Milestone Scientific, analysts believe Lucid Diagnostics is more attractive than Milestone Scientific.

Milestone Scientific has a beta of 1.409, which suggesting that the stock is 40.929% more volatile than S&P 500. In comparison Lucid Diagnostics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Milestone Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lucid Diagnostics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Milestone Scientific pays -- of its earnings as a dividend. Lucid Diagnostics pays out -- of its earnings as a dividend.

Milestone Scientific quarterly revenues are $2.5M, which are larger than Lucid Diagnostics quarterly revenues of $1.2M. Milestone Scientific's net income of -$1.5M is higher than Lucid Diagnostics's net income of -$12.4M. Notably, Milestone Scientific's price-to-earnings ratio is -- while Lucid Diagnostics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Milestone Scientific is 8.13x versus 14.20x for Lucid Diagnostics. Usually stocks with elevated PS ratios are considered overvalued.